IncludeHealth to Provide Musculoskeletal Care in Patients’ Homes in Partnership with Yale New Haven Health
December 13, 2022 04:00 ET
|
IncludeHealth
CINCINNATI, OHIO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- IncludeHealth, a digital musculoskeletal (MSK) health company, today announced a partnership with Yale New Haven Health System (YNHHS) to...
Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study
October 24, 2022 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical...
Researchers Investigate Nature’s Smallest “Social Cheaters”
September 14, 2022 12:30 ET
|
Burroughs Wellcome Fund
Research Triangle Park, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Being a member of a community often requires sacrifice. Species from across the animal kingdom have been shown to cooperate with...
Yale’s Department of Psychiatry Chair to Join Clearmind Medicine
June 21, 2022 09:00 ET
|
Clearmind Medicine Inc.
Dr. John H. Krystal, world-leading expert in alcoholism and depression, will serve on scientific advisory board VANCOUVER, June 21, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND,...
Blue Federal Credit Union Announces Grand Re-Opening of Denver Location
February 21, 2022 08:30 ET
|
Blue Federal Credit Union
Denver, Colorado, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Blue Federal Credit Union is excited to announce the grand re-opening of its south Denver branch located at 6460 East Yale Avenue. The opening...
Xanadu Bio Obtains Licenses and Options to Novel Platform Technologies from Yale University to Develop an Intranasal SARS CoV-2 mRNA Vaccine Booster Aimed at Inducing Local Mucosal Immunity to Prevent SARS CoV-2 Infection and Virus Transmission
February 08, 2022 07:30 ET
|
Xanadu Bio
~ Company licenses PACE, a next generation polymeric nanoparticle delivery platform, and options intranasal PACE/Spike mRNA and Spike recombinant protein vaccine boosters for the treatment of...
Study: New Intervention Helps with Alcohol-related Cognitive Impairment
December 14, 2020 08:00 ET
|
Posit Science
SAN FRANCISCO, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Researchers at Yale published positive results from a pilot study of a novel combination therapy in patients with Mild Cognitive Impairment related...
Cybrexa Therapeutics Expands Scientific Advisory Board With Appointment of Leader in Lung Cancer Research Roy Herbst, M.D., Ph.D.
August 03, 2020 07:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Cybrexa Therapeutics to Present First Efficacy and Safety Data From Its Lead Program CBX-12 and Initial Data From CBX-13 at the American Association for Cancer Research (AACR) Virtual Annual Meeting II
May 15, 2020 04:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., May 15, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Cybrexa Therapeutics Announces Expansion of Its Anticancer Pipeline
December 09, 2019 08:30 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today...